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Disclaimer 
All materials published in the Hong Kong Medical Diary 
represent the opinions of the authors responsible for the articles 
and do not reflect the official views or policy of the Federation 
of Medical Societies of Hong Kong, member societies or the 
publisher. 
Publication of an advertisement in the Hong Kong Medical 
Diary does not constitute endorsement or approval of the 
product or service promoted or of any claims made by the 
advertisers with respect to such products or services. 
The Federation of Medical Societies of Hong Kong and the 
Hong Kong Medical Diary assume no responsibility for any 
injury and/or damage to persons or property arising from 
any use of execution of any methods, treatments, therapy, 
operations, instructions, ideas contained in the printed 
articles. Because of rapid advances in medicine, independent 
verification of diagnoses, treatment method and drug dosage 
should be made. 
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On behalf of Executive Committee and Foundation Directors of the Federation, I would like to wish colleagues of 
our member societies and readers of our Medical Diary a very happy and healthy Year of the Rabbit. We would 
like to wish you all a productive year ahead, especially in working together for our professional fraternity and in 
contribution to health services for our patients and the society at large.
Time flies and last year has been a busy year for the Federation and Foundation too. The charity concert for our 
Foundation project in helping bereaved children had been a resounding success, and our first outing with a group 
of bereaved children was most gratifying and rewarding. A continuing series of activities will be rolled out this year 
for bereaved children, with a play therapy programme commencing soon. Please watch out for our announcement. 
Meanwhile further information on the project regarding referrals, volunteering or donation will be available from 
our secretariat, and we would be most delighted if you will join us in this very worthy cause.
The Federation will maintain the momentum in linking up and supporting our member societies. We shall actively 
engage our members in promoting health knowledge and information to professionals and public through various 
channels, as well as providing assistance with secretarial services and organising courses, seminars or annual 
meetings. Our general interest talks for fellow professionals proved popular last year, and this year we shall start 
with an overseas education talk exclusively for our members, co-hosting with the British Medical Association (Hong 
Kong) and supported by the British Council. A variety of interesting events will follow.
Looking forward to your participation, and meeting you in our various functions!
Message from the President 
Chinese New Year Message 
from the President
Dr. Raymond SK LO
President
The Federation of Medical Societies of Hong Kong
Dr. Raymond SK LO
Back :  Dr.Yin-kwok NG, Dr.Maureen Mo-lin WONG, Dr.Nancy Shi-yin YUEN, Dr.Chi-wai MAN, 
 Ms. Tina WT YAP, Dr. Gilberto Ka-kit LEUNG, Mr. Wilfred WONG
Front :  Dr. Dawson To-sang FONG, Dr. Susanna Sze-ching LO, Prof. Godfrey Chi-fung CHAN, 
 Dr. Raymond See-kit LO, Dr. Sai-kwing CHAN, Mr. Benjamin LEE
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Editorial
Dr. Yiu-wah FAN
This issue of the Medical Diary is dedicated to a few incidental 
conditions, which we commonly encounter during 'rountine' MRI or 
CT scans of the brain. 
As modern neuro-imaging is getting more widely available, we are 
referring more and more patients for brain scanning. Many patients 
actually ask for it as part of their health check. Undue anxiety 
sometimes arises after knowing the presence of a lesion in the brain. 
Many of these lesions are harmless while some require treatment. 
We will start with an article outlining the different choices of common 
neuro-imaging modalities at the present time and then follow by 
articles covering unruptured intracranial aneurysms, cavernous 
haemangiomas, arterial stenosis, and incidental pituitary lesions. In 
the drug session, we will revise on the common medications we use 
during neuro-imaging and some of the precautions that we need to 
be aware of.
Editor
www.apro.com.hk
Dr. Yiu-wah FAN
MBBS, FRCS, FHKAM
Specialist in Neurosurgery 
MBBS (HK), DFM (CUHK), 
DOM (CUHK), DDME(CUHK)
The Cover Shot
Photo is a snap shot at Chinese New Year 2010 near the riverside of  a 
branch of Songhua River (松花江 ), Jilin City (吉林市 ), Jilin Province (吉
林 省 ). Outside temperature was -16C. It was very wonderful to have 
such a quiet and peaceful sunset. My brain was totally immersed in the 
golden atmosphere of winter.
Dr. Kin-ming WONG
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This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the Medical 
Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded one CME credit under the programme 
upon returning the completed answer sheet to the Federation Secretariat on or before 28 February 2011.
Management of Unruptured 
Intracranial Cerebral Aneurysms
Dr. Yiu-wah FAN
Dr. Wai-man LUI
MBBS (HK), FRCS (SN) (Edin.), FRACS, FCSHK, FHKAM (Surgery)
Specialist in Neurosurgery
MBBS, FRCS, FHKAM
Consultant, Division of Neurosurgery
Dept of Surgery, The University of Hong Kong
Queen Mary Hospital
Dr. Wai-man LUIDr. Yiu-wah FAN
Findings of incidental unruptured intracranial cerebral 
aneurysms on MRI or CT brain examinations are getting 
more common. Epidemiology studies suggest that as 
many as 5% of people harbour a cerebral aneurysm 
by the age 75.8 Management of such aneurysms is 
becoming an important subject in our daily medical 
practice.
Treat or Observe?
The truly incidental aneurysms are those asymptomatic 
aneurysms in pat ients  without  any history of 
subarachnoid haemorrhage (SAH). This is a topic of 
major controversy. 
Aneurysm represents a weakening in the vessel. It is a 
degenerative disease with a tendency to enlarge with 
time. The probability of rupture is related to the size 
of the aneurysm. Aneurysm rupture is a devastating 
event. Approximately 15 percent of patients die prior to 
reaching the hospital and, of those who make it in time, 
only one-third will have a "good result" after treatment. 
Therefore, salvage treatment is not effective.
It is logical to think that one should treat the aneurysms 
before they rupture. For some time, neurosurgeons are 
eager to treat incidental aneurysms hoping to prevent 
subsequent ruptures and try to beat the natural history. 
The enthusiasm was dampened in 1998 when the 
International Study of Unruptured Intracranial 
Aneurysms ( ISUIA) 7 was  publ i shed.  I t  was  a 
retrospective study based in North America and Europe 
and is the biggest study on the subject at the present 
time. It quoted a rupture rate of 0.05% per year for 
aneurysms smaller then 10mm and, 0.5% per year for 
aneurysms larger than 10mm. This is much less than 
what we have formerly believed. Using these figures 
to compare the treatment risk of about 10% (mortality 
and morbidity combined), one would find it difficult to 
recommend prophylactic treatment for any aneurysm 
less than 10mm.
The study was, however,  heavily criticised for 
recruitment and selection bias, and it prompted a 
prospective study. In the 2003 prospective ISUIA study, 
the 5-year cumulative rupture rates for patients who 
did not have a history of subarachnoid haemorrhage 
with aneurysms located in the internal carotid artery, 
anterior communicating artery, anterior cerebral artery, 
or middle cerebral artery were 0%, 2.6%, 14.5%, and 40% 
for aneurysms less than 7 mm, 7–12 mm, 13–24 mm, and 
25 mm or greater, respectively, compared with rates of 
2.5%, 14.5%, 18.4%, and 50%, respectively, for the same 
size categories involving the posterior circulation and 
posterior communicating artery aneurysms.9 This 7mm 
size is now regarded as the cutoff for treatment by most 
neurosurgeons.
Although the ISUIA-II study settled some controversies, 
what remained puzzled is why we are seeing many 
small aneurysms, less than 7mm, rupture with SAH 
and yet the ISUIA study was telling us that they have 
a very low risk of rupture. From a recent study, 71.8% 
of ruptured aneurysms were smaller than 7 mm, and 
87.9% were smaller than 10mm. 3
Among many of us, the belief is that small aneurysms 
can also rupture and it is better to secure them if 
technically feasible. 
When one makes the decision for treating an incidental 
aneurysm, one does not only take in consideration 
the size alone. The morphology of the aneurysm is 
also important. The presence of a daughter sac in the 
aneurysm, representing a weak point in the aneurysm, 
will prompt for intervention. Patients with a history of 
previous SAH, an aneurysm at the posterior circulation, 
a family history of SAH and patients with autosomal 
dominant polycystic kidney disease (ADPKD) all pose 
higher risks of ruptures.
Making the decision of whether to treat or not is a 
complex issue and we will consider the following:
Factors favouring treatment for incidental aneurysms
1. size >7mm
2. posterior circulation <including PcoA>  aneurysm
3. presence of daughter sac (representing a weak point 
in the aneurysm)
4. long life expectancy, (young age)
5. history of SAH in the past
6. family history of SAH
7. patient with ADPKD
In the ISUIA study9, the treatment risk (combined 
morbidity and mortality) at 1 year was 12.6% for 
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clipping and 9.8% for coiling. Although a simple 
comparison of treatment risk and natural history can 
be calculated, one has to take into consideration the 
psychological factor. No matter what the statistics show, 
no one can guarantee a risk-free choice. After explaining 
the pros and cons, we have to take care of the patient’s 
psychology and help them make decision. If the patient 
cannot accept the psychological burden of having a 
'time bomb' in his /her head, treating a small aneurysm 
may be justified.
Screening for Aneurysms
It is generally believed that routine screening for 
aneurysms in the general population is not indicated. 
If it is to be carried out, it should be targeted to specific 
subpopulations at increased risks. 
Specific genetic syndromes that are associated with 
an increased risk of SAH include the Ehlers-Danlos 
syndrome type IV, Marfan syndrome and autosomal 
dominant polycystic kidney disease (ADPKD). Among 
them, ADPKD is most indicated for screening.2
If two or more members of the family are affected 
with aneurysms, screening is recommended for the 
first-degree relatives. Screening with MRA or CTA is 
recommended to start in their twenties and then every 5 
to 10 years thereafter.  
Patients with treated aneurysms may develop new 
aneurysms with time.4 Rinne and Hernesniemi 
suggested in their study of 1150 aneurysm patients, that 
individuals who present with SAH before the age of 40 
may be particularly susceptible to aneurysm formation 
and may benefit from screening at 5-year intervals.6
If we choose not to do surgery, what 
can we do to help? 
It  has been shown that cigarette smoking, and 
hypertension are associated with aneurysm formation. 
Controlling these risk factors theoretically will help the 
situation.
How often we should do follow up 
angiograms?
It is common practice to follow up patients with UIA 
with angiogram. There is really no guideline on this 
subject. Depending on the size of the lesion, and the 
intention of the patient, if it is approaching the 7 mm 
cutoff and the patient is ready to have it treated, then 
we will do the follow-up angiograms more frequently. 
A yearly follow up is our usual practice.
We use MRA for follow-up. MRA can be done without 
radiation and contrast. Bear in mind that we may need 
to do many follow up angiograms, especially if the 
patient is young. Although MRA is not as accurate as 
DSA for small aneurysms (< 5 mm), it does not really 
matter if we are using 7 mm as the cutoff for treatment.
Shall we treat immediately if we see a 
small growth of aneurysm on follow-
up? Or shall we wait until it is bigger 
than 7 mm?
Although we tend to believe most aneurysms grow in 
a linear fashion, they sometime can enlarge rapidly. 
From the statistical point of view, there may not be any 
difference in bleeding risks for a 4 mm aneurysm and 
a 6 mm aneurysm. We look upon a growing aneurysm 
as an unstable aneurysm and we tend to treat it when 
there is documented growth on follow up angiograms, 
especially if the growth is irregular.
During observation of an unruptured 
incidental aneurysm, is it safe to use 
antiplatelet and anticoagulant?
It is understandable that SAH will be more devastating 
during aneurysm rupture  i f  the  pat ient  i s  on 
medications that hinder haemostasis. As vascular 
diseases are prevalent, there is an increasing need 
for such medications. When confronted with such a 
problem, we continue to prescribe antiplatelet and 
anticoagulant if there is a clear indication for them. We 
tend to believe that these medications do not actually 
increase the chance of ruptures, but they will make 
things worse if a rupture occurs.  Having said that, the 
weighting for treating the aneurysm will be higher in 
such circumstances.
What treatment? Clip or coil / stent?
Once the decision has been made for treatment, we have 
a choice of open clipping and endovascular treatment 
(coiling and stenting). 
With  the  rapid  development  of  endovascular 
technology,  and support  of  the  Internat ional 
Subarachnoid Aneurysm Trial (ISAT)5 (which showed 
less complication with coiling than open clipping in 
patients with ruptured aneurysms), both patients and 
doctors are gradually siding towards endovascular 
treatment. However, one should be careful in assessing 
the end point of treating unruptured aneurysms, in 
which long-term secure control is the aim, especially 
in young patients. Clipping has a long track record for 
good secure control whereas endovascular treatment is 
often associated with recurrences and requirement for 
retreatment.
If the patient is younger than 50 year old and the 
aneurysm is technically easy to clip, there is a point 
of going for open clipping. Otherwise, endovascular 
management seems to be the treatment of choice 
especially for posterior-circulation aneurysms.
In the ISUIA study, the combined morbidity and 
mortality rates at 1 year were 12.6% for clipping and 
9.8% for coiling. These are general figures including 
treatment for large difficult aneurysms, which we know 
are associated with a high morbidity. With further 
development in technology, we expect to see lower 
Medical BulletinVOL.16  NO.2  FEBRUARY  2011
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management mortality and morbidity in the future. 
Recent reports, especially with endovascular treatment, 
have demonstrated a very low risk of treatment (1.5%).1 
Having said that, one very important factor in keeping 
the treatment risk low is to adopt a conservative attitude 
during surgery for unruptured aneurysms.  At the 
time of operation, if there is any difficulty, one should 
reconsider the need to press on when the risk becomes 
substantial.
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MCHK CME Programme Self-assessment Questions
ANSWER SHEET FOR FEBRUARY 2011
Answers to January 2011 Issue
Please read the article entitled “Management of Unruptured Intracranial Cerebral Aneurysms” by Dr. Yiu-
wah FAN and Dr. Wai-man LUI and complete the following self-assessment questions. Participants in the 
MCHK CME Programme will be awarded 1 CME credit under the Programme for returning completed answer 
sheets via fax (2865 0345) or by mail to the Federation Secretariat on or before 28 February 2011. Answers to 
questions will be provided in the next issue of The Hong Kong Medical Diary.  
Questions 1-10: Please answer T (true) or F (false) 
Please return the completed answer sheet to the Federation Secretariat on or before 28 February 2011 for 
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) 
self-assessment questions. 
1. Most intracranial aneurysms are congenital in nature and are present at birth.
2. The prevalence of unruptured intracranial aneurysms in the general population is up to 5%. 
3. The immediate mortality rate for ruptured intracranial aneurysms is 50%.
4. Posterior communicating artery aneurysms have a lesser tendency to rupture compared with anterior     
 communicating artery aneurysms.
5. Presence of a daughter sac in an aneurysm is a risk factor for rupture.
6. Smoking has a favourable effect on aneurysm rupture.
7. Patients with autosomal dominant polycystic kidney disease have a higher incidence of cerebral aneurysm. 
8. Screening for cerebral aneurysms is well established for the general population.
9. There is no chance of rupture for aneurysms smaller than 5mm in diameter.
10. Endovascular treatment of cerebral aneurysms has poorer immediate outcome compared with craniotomy and  
 clipping.
An Update in AF Management
1 4 82 5 93 76 10
1. T T T T T F TF F F4. 8.2. 5. 9.3. 7.6. 10.
Name (block letters):___________________________________ HKMA No.: _________________________________
HKID No.: __ __ - __ __ __ __ X X (X) HKDU No.: _________________________________
Contact Tel No.:_______________________________________ CDSHK No.: ________________________________
Management of Unruptured Intracranial Cerebral Aneurysms
Dr. Yiu-wah FAN Dr. Wai-man LUI
MBBS, FRCS, FHKAM
Specialist in Neurosurgery 
MBBS, FRCS, FHKAM
Consultant, Division of Neurosurgery
Dept of Surgery, The University of Hong Kong
Queen Mary Hospital
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Contrast Agents for Neuro-imaging
Dr. Kai-ming AUYEUNG
Dr. Gladys LO
Dr. Gladys LODr. Kai-ming AUYEUNG
Neuro-imaging is essential for making a diagnosis of 
the central nervous system diseases.  Although intrinsic 
tissue contrast is present in the CT/MR images, neuro-
imaging also relies heavily on contrast media to improve 
lesion detection (sensitivity) and to aid in lesion 
characterisation (specificity).  Furthermore, contrast 
could be used for functional assessment of physiologic 
processes including perfusion/blood flow and vascular 
status. During the cerebral angiography, contrast is 
injected via the catheter to opacify the intracranial 
arteries. Contrast agents are essential for contemporary 
neuro-diagnosis.  Although rare, contrast reactions do 
occur and one must be aware of this. Adverse reactions 
are more common with CT contrast agents ('iodinated' 
contrast) than with MR contrast agents ('gadolinium' 
contrast). 
CT Scan
Since the contrast could not pass through the blood-
brain barrier (BBB), only vascular structures and areas 
of the brain that have no BBB (such as choroid plexus, 
pineal and anterior lobe of pituitary gland) enhance 
normally.  Three pathologic (abnormal) enhancements 
occur.1 1) Abnormal enhancement within enlarged 
vessels without breakdown of BBB, including AVM or 
neoplasm with enlarged vascular spaces. 2) Breakdown 
of BBB with leakage of contrast e.g. neoplasm, infarction 
and inflammation. 3) Lesions with no BBB such as 
meningioma, acoustic schwannoma. 
Adverse reactions happen after contrast administration. 
They are more common with the 'iodinated' contrast 
than with 'gadolinium' contrast. Most adverse effects 
after iodinated contrast are mild or moderate, which do 
not require treatment.  Approximately 3% of patients 
undergoing contrast examination will have some types 
of reaction, usually mild vasomotor symptoms. About 
0.03% will require hospitalisation and 1.6% requires 
treatment.1 Reactions leading to death are rare and 
occur in about 1:250,000 patients. 
The contrast reaction is classified into:2
1) Mild Reaction (no need for treatment): Nausea/
vomiting, urticaria. 
2) Moderate  Reac t ion  (no t  immedia te ly  l i f e 
threatening but often requires treatment) : Vasovagal 
reaction, mild bronchospasm or hypotension.  
3) Severe Reaction ( potentially or immediately 
life threatening):  severe vasovagal reactions, 
hypotension or bronchospasm, laryngeal oedema 
and cardiac arrest.  
4) Organ-specific Effect:  pulmonary oedema or seizure
5) Delayed (0.5% to 9%):  headaches, muscle pains 
and flu-like symptoms up to 48 hours after contrast 
media.  Delayed cutaneous reactions ranging from 
3 hours to 7 days after contrast injection, most often 
with exanthem (self-limited). 
Prior sensitisation to the contrast agent is not required 
for an adverse reaction to occur. There is no reliable 
screening test to predict which patients will have a 
severe reaction. Most reaction occurs within a few 
minutes of injection. High-risk patients (those with 
a history of allergy or asthma) should be pre-treated 
with steroids but it does not guarantee an absence 
of reactions.  Patients with a history of documented 
iodinated contrast reaction should not be injected with 
iodinated contrast. It is better to consider alternative 
examinations such as MRI with gadolinium contrast. 
The iodinated contrast  media can damage the 
kidneys (contrast nephrotoxicity). Patients with renal 
dysfunction taking Metformin could have risks of lactic 
acidosis and therefore, Metformin should be suspended 
at the time of contrast injection. 
MR Imaging
In the presence of intact BBB, most of the normal 
neuronal structures will not enhance as in CT scan. 
Any pathology that disrupts the BBB will enhance 
after IV contrast injection. In order to avoid erroneous 
interpretation of the contrast enhancing lesion, 
unenhanced images must be available for comparison.3 
Gadolinium chelates are extremely well tolerated by 
the vast majority of patients.  The frequency of all 
acute events after an injection of 0.1 or 0.2mmol/kg of 
gadolinium chelate ranges from 0.07% to 2.4%.  The vast 
majority of these reactions are mild.  'Allergic' responses 
are unusual (0.004% to 0.7%), including urticaria and 
very rarely bronchospasm. Severe life-threatening 
reactions are exceedingly rare (0.001% to 0.01%). Persons 
with asthma and various allergies are also at greater 
risks (up to 3.7%). 2
Gadolinium agents  are  considered to have no 
nephrotoxicity at approved dosages. However, they 
can result in nephrogenic systemic fibrosis (NSF) for 
patients with actual renal failure or severe chronic 
kidney disease. NSF is a fibrosing disease, which will 
primarily be identified in skin and subcutaneous tissues 
but will also involve other organs including the lung, 
oesophagus, heart and skeletal muscles.  It is estimated 
that patients with severe chronic kidney disease 
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(GFR<30) have a 1% to 7% chance of developing NSF 
after exposure to gadolinium agents, especially high 
doses or multiple doses.  There has been no report of 
NSF in patients with normal renal function.  Therefore, 
estimated GFR is recommended to be obtained 
within six weeks of a Gadolinium-enhanced study in 
patients with renal disease, over 60 years of age, with 
hypertension, DM, or severe liver disease. In patients 
with GFR<15 ml/min/1.73m2, the risk of NSF is greatest 
and there therefore should be absolute avoidance of 
contrast MRI.  Alternative examinations should be 
suggested. For patients with GFR that is abnormal but 
greater than 15ml/min/1.732m2, judicious use of the 
lowest possible doses of selected macrocyclic agents are 
recommended. 
The intra-thecal contrast (MR cisternography) is 
used for the diagnosis of Cerebrospinal fluid (CSF) 
rhinorrhea and spontaneous intracranial hypotension 
(SIH), which imply an abnormal communication 
between the subarachnoid space and nasal cavity 
or spinal canal. For these patients, confirmation, 
localisation and characteristics of the actual site/
sites of CSF leak are challenging but important for 
treatment planning.4-10 Conventional myelography is 
now obsolete. Radionuclide cisternography (RC) has 
radiation hazards and poor spatial resolution. CT scan 
is sensitive for bony lesions but impossible to confirm 
the site of active CSF leak. Non-enhanced MR imaging 
has some use in demonstrating CSF fistulae but with 
relative high frequency of false positive findings of up 
to 42% and also false negatives.5, 23-24 CT cisternography 
is more reliable. It can identify the spinal level of a CSF 
leak in 67% of patients compared with 50% and 55% 
with spinal MRI and RC respectively21-22 but requires 
scanning of the whole spine and skull base. The patients 
will receive a considerable dose of radiation. The bony 
structures may also partially obscure the subtle site of 
CSF leakage.
MR cisternography can demonstrate the site of CSF 
leakage but with no radiation or bone artifacts.  It 
requires a lumbar puncture and followed by a single 
low-dose gadolinium injection into the lumbar 
subarachnoid space. Many studies showed the relative 
safety and feasibility of low-dose gadolinium-enhanced 
MR cisternography in confirming and determining the 
focus of active CSF leaks. The results of initial human 
studies also revealed that the procedure do not manifest 
clinical evidence of gross physical or neurologic 
abnormalities, CSF changes, or electroencephalographic 
alterations.11-18 The adverse reactions are rare, including 
nausea/vomiting, headache, anaphylactoid reaction and 
seizure.  
Conclusion
Contrast agents used for CT, MRI scan and cerebral 
angiography play an important role in neuro-imaging. 
Although they are safe for use, adverse reactions may 
happen and therefore any contrast should be used 
judiciously.  Recently, MR cisternography is more often 
used for the investigation of SIH and CSF rhinorrhea.  
(with acknowledgment of Mr. Raymond Lee). 
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Cavernous Haemangioma of Brain
Dr. Ching-fai FUNG 
Dr. Ching-fai FUNG
Introduction
Intracranial cavernous haemangioma (CH) was an 
uncommon pathology before the introduction of MRI 
examination. It was regarded as a mysterious pathology 
in neurological diagnosis because the lesion could not 
be easily revealed by cerebral angiogram or CT scan. It 
was therefore given the description of angiographically 
occult vascular malformation or cryptic vascular 
malformation.
When MRI became a common screen examination, CH 
became a common pathology identified in a routine 
MRI examination of the brain. 
Pathology
CH consists of a group of thin walled vessels as 
discrete, lobular and well circumscribed lesions inside 
the parenchyma of the brain. Grossly it appears as a 
raspberry-like lesion red to purple in colour (Figure 1).
Microscopically it consists of dilated thin walled 
capillaries with variable thin fibrous adventitia devoid of 
smooth muscle and elastin. There is no brain parenchyma 
between the vascular channels. Haemosiderin deposits 
are always present inside the surrounding normal 
parenchyma indicating that diapedesis of red blood cells 
is a common event in all CHs.
Figure 1 - Cavernous haemangioma after surgical removal as 
raspberry-like lesion.
Diagnosis
Clinical diagnosis of intracranial CH is impossible. Skull 
x-rays may occasionally reveal fine calcifications at the 
lesion but the finding is not diagnostic.
CT scan may be  tota l ly  normal  in  most  CHs. 
Hyperintense signals may be seen if old blood is 
accumulating. Enhancement after contrast CT scan is 
variable and is usually not diagnostic.
CH is well known to be invisible in cerebral angiograms 
and is therefore called angiographically occult. 
Occasionally venous pooling at the lesion may be seen 
and is again not diagnostic.
MRI is  the most  important  imaging study for 
confirmation of the diagnosis (figure 2).  In the 
absence of overt haemaorrhage, most CHs appear as a 
hyperintense lesion with a faint hypointense rim in T1 
and lobulated heterogenous signals with a hypointense 
rim in T2. The most diagnostic image appears in the 
gradient-echo MRI which produces a blooming artifact 
from the magnetic susceptibility effect of haemosiderin. 
CH therefore appears characteristically as a dense 
hypointense signal in the gradient-echo MRI.9
Figure 2 - Cavernous haemangioma appears in T1, T2 and 
gradient-echo MRI.
Epidemiology
CH of the brain is found in 0.1% to 4 % of all vascular 
malformations of the brain. In 4,068 cases of prospective 
autopsy study, McCormick identified CH in 0.4%, 
arteriovenous malformations in 0.6%, telangiectases in 
0.7% and venous malformations in 2.6%.8
There is no sex prevalence and most symptomatic cases 
are found between 20 to 40 years old. 
A b o u t  7 5 %  o f  t h e  l e s i o n s  a r e  l o c a t e d  i n  t h e 
supratentorial region (1/4 in the frontal and 1/6 in the 
temporal lobes) and 25% in the infratentorial region (50% 
in the pons or brainstem).
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Multiple lesions are reported in 8 to 18 % of cases (figure 
3). Multiple CHs are common in the south-western 
part of the United States among Hispanic patients. 
Familial incidence is reported in 50% of multiple CHs 
and an autosomal dominant inheritance with variable 
penetrance is suspected. There is no convincing 
hereditary link with single lesions.4
Figure 3 - Multiple Cavernous haemangioma 
Clinical Presentation
The majority of CHs are found incidentally with no 
clinical symptoms. It is associated with headaches less 
commonly than arteriovenous malformations. Two 
major clinical symptoms related to CH are bleeding and 
epilepsy.
Haemorrhage in CH
The presence of haemosiderin around the lesion is 
commonly found and represents diapedesis of red 
blood cells through the thin walled vessels. This results 
in surrounding gliosis with a fibrotic layer covering the 
lesion. Minor intralesional bleeding and thrombosis 
are also commonly found in incidental cases. All 
these findings should not be considered as overt 
haemorrhage.
Robinson defined overt haemorrhage as acute or 
subacute blood accumulation outside the haemosiderin 
ring of the lesion (Figure 4). With this definition, the 
incidence of overt haemorrahage in virgin cases is 
estimated at 0.7% per lesion per year. However the 
risk of rebleeding after an overt haemorrhage is 25% 
in one year without treatment.6,7,10 Rebleeding after the 
first haemorrhage is often related to physical exertion. 
Incidents of overt haemorrhage are more common 
in females. A higher chance of haemorrhage during 
pregnancy has been suggested. The consequence of 
overt haemorrhage is seldom fatal. The presentation 
depends on the location of the lesion.
Overt haemorrhage in supratentorial lesions is 
commonly associated with progressive hemiparesis and 
is often misdiagnosed as tumours in initial CT scan. 
Occasionally extensive intraventricular haemorrhage is 
found in periventricular lesions (figure 5). 
Bleeding in the brainstem from CH is more serious 
and sixth nerve palsy with diplopia is a common initial 
presentation followed by multiple cranial nerve palsy, 
ataxia and long tract signs. Coma and life threatening 
brainstem insult can occur as a consequence of recurrent 
bleeding.
The chance of haemorrhage is independent of the lesion 
size. However bleeding from a large CH often results in 
significant neurological impairment that needs surgical 
treatment.
Figure 4 - Overt haemorrhage form cavernous haemangioma 
with acute blood outside the haemosiderin ring.
Figure 5 - Bleeding into third ventricle from a periventricular 
cavernous haemangioma.
Epilepsy in CH
The actual incidence of epilepsy in patients with 
supratentorial CH is unknown. More incidents of 
epilepsy should be found in patients with CH at 
the hippocampus and motor area (figure 5). The 
abnormal vessels themselves are not epileptogenic. 
The surrounding tissue is rendered epileptogenic 
with the effect of pressure and trophic factors such as 
haemosiderin. 
Treatment
Most CHs are diagnosed as incidental findings in MRI 
during investigation for other problems. As the risk of 
spontaneous bleeding is low and seldom catastrophic, 
treatment is not required if there is no clinical 
Medical BulletinVOL.16  NO.2  FEBRUARY  2011
    16
symptoms. However a detailed history is often required 
to exclude the presence of complex partial seizure which 
is often ignored by patients. 
Figure 6 -avernous haemangioma at the hippocampus with 
epilepsy.
Conservative Treatment
Conservative treatment for overt bleeding in CH is 
often successful if neurological impairment is not 
significant. If rebleeding is minimised by the reduction 
of physical activities and tranexamic acid, neurological 
improvement is usually seen in a few weeks to a few 
months (figure 7). The patient is advised to withhold 
all activities that will increase venous pressure in the 
subsequent year.
Figure 7 - Bleeding in a brainstem cavernous haemangioma (a) 
and resolution of blood signal after conservative treatment (b).
Surgical Treatment
Surgical removal is the only effective method for 
elimination of a CH.  It is not a difficult procedure event 
in the brainstem. The existing gliosis around the CH 
serves as a good layer for microscopic dissection of the 
lesion without major damage to normal tissues. The 
use of navigator and microscopy allows safe removal of 
deep seated lesions.
However the indication for surgery must be justified. 
The common indication for surgical removal is a 
significant neurological impairment as a result of 
repeated haemorrhages resulting in a mass effect. 
Epilepsy Treatment
CH is commonly found in investigations for poorly 
controlled epilepsy, especially in the hippocampus. 
Surgical removal of the CH for control of epilepsy 
is suggested if the epileptic focus is confirmed by 
electrophysiology studies. Good surgical result in the 
control of epilepsy has been reported at 70% complete 
seizure free after operation.2, 3
Removal is usually performed with clearance of the 
surrounding haemosiderin-loaded brain parenchyma in 
order to remove the epileptogenic zone. However there 
is a controversy in this point because no significant 
difference is found between surgical removal of the 
lesion alone and removal of surround haemosiderin.
Radiosurgery
The use of radiosurgery such as the Gamma Knife for 
treatment of CH remains debatable. There is a lack of 
convincing evidence in the literature to support the 
effectiveness of radiosurgery for the elimination of CH. 
The benefit of such therapy must be carefully evaluated 
against the potential radiation toxicity.1, 5
Summary
Cavernous haemangioma of brain is a common 
incidental finding in MRI examinations. The associated 
clinical events are haemorrhage and epilepsy. The risk 
of overt haemorrhage is 0.7% per lesion per year for 
virgin cases. Active treatment is usually not required 
for asymptomatic cases. Surgical removal is the only 
confirmed effective method for elimination of the CH 
and is indicated for progressive neurological impairment 
from repeated bleeding and uncontrolled epilepsy.  
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Introduction
Intracranial arterial stenosis is used to be thought of 
as an uncommon cause of ischaemic stroke in Western 
literatures, accounting for about 10% in whites.1-2 Wong 
in 20063 reported that larger artery intracranial stenosis 
affecting the middle cerebral artery, intracranial portion 
of the internal carotid artery, vertebrobasilar artery and 
posterior and anterior cerebral artery is more common 
in Asian patients. In fact, it is estimated to account 
for 33-50% of strokes and 50% of transient ischaemic 
attacks in the Chinese population; it was also found 
in 47% of patients with stroke in Thailand; and it was 
significant in approximately 48% of patients with stroke 
in Singapore. 
Natural History 
There are several important clinical trials that 
would give a clearer picture of the risks of strokes in 
patients having a large intracranial artery stenosis. 
The Extracranial-Intracranial (EC-IC) Bypass Study4 
provides prospective data on the risk of stroke in 
patients with symptomatic carotid siphon or middle 
cerebral artery (MCA) stenosis. In this trial, patients 
with carotid siphon or MCA stenosis who were treated 
medically (management of risk factors and 1300 mg/d 
aspirin) had an annual stroke rate of 8% to 10%. 
Patients with symptomatic intracranial vertebral artery 
or basilar stenosis are at a higher risk of stroke, MI, or 
sudden death. Upon following up of 68 patients with 
50-99% stenosis in the vertebrobasilar arteries for a 
median period of 13.8 months , 15 patients (22%) had an 
ischaemic stroke (4 fatal), 3 patients (4.5%) had a fatal 
myocardial infarction (MI) or sudden death. Overall, the 
estimated stroke risk of patients having a severe degree 
of arterial stenosis ranged from 10-20% yearly. 
Medical treatment of Atherosclerotic 
Intracranial Arterial Stenosis
Antiplatelet vs. Anticoagulant
Calpan5 proposed a pathophysiological rationale 
for anticoagulation to suggest warfarin is a common 
treatment choice for symptomatic intracranial stenosis. 
However ,  the  Warfar in-Aspir in  Symptomat ic 
Intracranial Disease (WASID) trial6 showed that 
aspirin was safer and as effective as warfarin for stroke 
prevention in patients with symptomatic intracranial 
stenosis. WASID was stopped early after a mean follow-
up of 1.8 years because of higher rates of death and 
major haemorrhage in the warfarin arm. The primary 
end point of ischaemic stroke, brain haemorrhage or 
vascular death, occurred in 22.1% of patients assigned 
aspirin and 21.8% of those in the warfarin group. The 
rates of myocardial infarction or sudden death were also 
higher in the warfarin arm.  Even in the vertebrobasilar 
arterial stenosis with a higher risk of stroke, there is no 
clear evidence of any benefit of warfarin over aspirin.
Other antiplatelet agents (e.g.  clopidogrel and 
combination of dipyridamole/aspirin) have been shown 
to have similar stroke recurrence rates in patients with 
various underlying causes of stroke and in a subset 
of patients with large artery atherosclerosis in the 
Prevention Regimen for Effectively Avoiding Second 
Strokes (PRoFESS) Study.7 In summary, aspirin should 
be the drug of choice unless not tolerated by the patient. 
Endovascular Therapy
Angioplasty and stenting have emerged as therapeutic 
options for symptomatic intracranial stenosis over 
the past few decades. Initially the risk of angioplasty 
was very high by borrowing the hardware from the 
cardiologists. Since that time, advances in microcatheter 
and balloon technology, the high risk of recurrent 
strokes in patients with intracranial stenosis despite 
medical management in WASID, and the success 
of endovascular treatments for other intracranial 
diseases have led to a renewed interest in intracranial 
angioplasty and stenting.
Angioplasty alone
Retrospective angioplasty studies reported high 
technical success rates with reduction of stenosis to 
<50%, but the 30-day rate of stroke or death has varied 
widely (4-40%). Restenosis rates after angioplasty have 
been reported between 24-50%.8  
Overall, available data on intracranial angioplasty 
suggest that it can be performed relatively safely in stable 
patients, but the long-term outcome after angioplasty 
has not been prospectively studied. Moreover, there are 
numerous technical drawbacks to angioplasty including 
immediate elastic recoil of the artery, dissection, acute 
vessel closure, residual stenosis after the procedure, and 
high restenosis rates.
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Angioplasty plus Stenting
The Wingspan system is currently the only FDA-
approved device for treating symptomatic intracranial 
stenosis. In 2005, the Wingspan Stenting System 
(Boston Scientific) was approved by the FDA for use 
under an HDE (humanitarian device exemption) in 
patients with symptomatic intracranial stenosis who 
are refractory to medical therapy. Hong Kong was also 
one of the study sites. It was a prospective multicentre 
international Phase I trial which included 45 patients 
with symptomatic 50% to 99% intracranial stenosis 
who had recurrent strokes despite antithrombotic 
therapy. The technical success rate was 97.7% and the 
30-day stroke or death rate was 4.5%. The 1-year rate of 
ipsilateral stroke was 9.3%. The restenosis rate was 7.5% 
at 6 months and none was symptomatic.9
In WASID the most important baseline predictors of 
stroke in the territory were severity of stenosis and time 
from qualifying event to enrollment. The rate of stroke 
in the territory in patients with >70% stenosis was 18% 
at 1 year (95% CI =13% to 24%) vs. 7% at 1 year (95% CI = 
5% to 10%) in patients with <70% stenosis. The National 
Institute of Health (NIH) recruited patients from sixteen 
medical centres enrolled consecutive patients being 
treated with a Wingspan stent in this registry between 
November 2005 and October 2006. A total of 129 patients 
with symptomatic 70-99% intracranial stenosis were 
enrolled.  The technical success rate was 96.7%. The 
frequency of any stroke, intracerebral haemorrhage, 
or death within 30 days or ipsilateral stroke beyond 30 
days was 14.0% at 6 months. The frequency of >50% 
restenosis on follow-up angiography was 13/52 (25%). 
The results indicate that the observed rates of any stroke 
or death within 30 days or stroke in the territory beyond 
30 days are similar in the two groups up to 3 months 
but diverge afterwards (lower in the stented patients).
Comparison of the event rates in high-risk patients in 
WASID vs. this registry does not rule out either that 
stenting could be associated with a substantial relative 
risk reduction (e.g., 50%) or has no advantage compared 
with medical therapy. Further randomised control study 
is required. 
Future Directions
The best treatment for prevention of another stroke or 
TIA in patients with narrowing of one of the arteries 
in the brain is uncertain. There are several aspects 
that clinicians should be focused and require further 
research. 
Aggressive management of risk factors
In WASID, elevated blood pressure was significantly 
associated with an increased risk of ischaemic stroke.6 
Raised low density lipoprotein (LDL) was also strongly 
associated with poor outcomes in patients, because 
25.0% of patients with LDL >115 mg/dL had the primary 
end point compared with 18.5% of patients with a mean 
LDL<115 mg/dL Among the mere 10% of patients with 
mean LDL <70 mg/dL only 7% had a primary end point 
compared to 23% of the patients with LDL >70 mg/dL 
(P<0.09). 
Recent research has also indicated a benefit in the 
prevention of recurrent strokes by Intensive Medical 
Therapy, which is defined as treating risk factors for 
stroke like high blood pressure, elevated LDL (low 
density lipids - the "bad" form of cholesterol) and 
diabetes.10 
Clinical trial
The Stenting and Aggressive Medical Management for 
Preventing Recurrent stroke in Intracranial Stenosis 
(SAMMPRIS) Trial is a NIH sponsored, on-going 
randomised trial at 60 US sites designed to determine 
whether angioplasty and stenting plus aggressive 
medical management is superior to aggressive medical 
management alone for the prevention of recurrent 
stroke in patients with 70% to 99% stenosis of a major 
intracranial artery.11 Patients will be randomised 1:1 
to either arm. Aggressive medical management in 
SAMMPRIS will consist of dual antiplatelet therapy 
(aspirin+clopidogrel) for 90 days in all patients. All 
patients will also receive protocol driven risk factor 
management targeting a LDL <70 mg/dL and systolic 
blood pressure <140 mm Hg (<130 if diabetic) and 
a comprehensive lifestyle modification programme 
to assist with weight reduction, exercises, smoking 
cessation, and nutrition.
Summary
Symptomatic atherosclerotic intracranial stenosis is a 
high-risk condition. WASID showed that aspirin is safer 
and as effective as warfarin for preventing recurrent 
strokes. Angioplasty and stenting cannot be justified in 
patients with < 70% stenosis, given the low risk of stroke 
in the territory of a stenotic artery (6 % at 1 year) and the 
inherent risk of current technology. Patients with severe 
stenosis, recent ischaemic symptoms and an NIH stroke 
scale score of > 1, and females are at the highest risk for 
strokes, and therefore have the greatest likelihood of 
benefiting from angioplasty and stenting.12 The linear 
relationship between the degree of stenosis and stroke 
risks with medical therapy also supports a mechanical 
approach to revascularisation. At present, however, 
there is no level 1 evidence to support angioplasty and 
stenting for patients with symptomatic intracranial 
atherosclerotic disease. A randomised controlled 
trial is needed to prove the efficacy of this therapy. It 
should also be noted that these patients as a group have 
frequent vascular risk factors and will require aggressive 
medical management. In addition, rates of restenosis 
and the clinical consequences of restenosis will need to 
be closely monitored in future studies.
Fig. 1a. 56-yr old lady presented 
with recurrent TIA. Cerebral 
DSA showing a 90% right MCA 
stenosis. 
Fig. 1b. Cerebral angiogram 
showing complete recanalization 
of right MCA after stenting with 
a 3mm x 15mm Wingspan stent. 
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Introduction
Magnetic resonance imaging (MRI) studies and 
computerised tomography (CT) are becoming more 
readily available and widely used modalities of clinical 
investigations. An increasing number of mass lesions 
involving the sellar region are now being detected 
on MRI and CT performed for reasons unrelated 
to pituitary diseases. These incidental sellar lesions 
include neoplastic conditions such as pituitary 
adenomas, meningiomas, craniopharyngiomas, 
gliomas and metastases. Non-neoplastic lesions may 
include Rathke’s cleft cysts, carotid artery aneurysms, 
granulomas, hypophysitis, mucocoeles, and other 
uncommon pathologies. This article will focus on the 
two most commonly encountered entities - incidental 
pituitary adenomas1 and Rathke’s cleft cysts.2
Pituitary Incidentaloma (PI)
The incidence of PI is  around 10% at autopsy, 
distributed equally throughout the age groups and 
between the sexes. The reported incidences of PI on 
contrasted MRI range widely from 2 to 34 %. It is of 
note that some normal individuals may have ‘normal 
pituitary hypertrophy’ that exceeds the normal size 
boundary of 9 mm, and which may occasionally mimic 
a PI. Artefacts such as beam-hardening effects on CT 
and susceptibility distortions on MRI may also cause 
diagnostic difficulties.
PI may be functioning (hormone-secreting) or non-
functioning lesions. However, about 75% of the latter 
are in fact gonadotroph adenomas, and others may stain 
positively for adrenocorticotropic hormone (ACTH), 
growth hormone (GH), prolactin (PRL) or thyrotropin 
(TSH) singly or in combinations. These are sometimes 
referred to as ‘silent’ corticotroph, somatotroph, 
lactotroph, thyrotroph or mixed adenomas, respectively.
Clinical presentation
The fact that these adenomas are incidental findings 
does not necessarily mean that they are clinically silent. 
A detailed history and clinical examination are essential 
for the detection of subtle symptoms and signs that 
may suggest hormonal hypersecretion, hypothalamic/
pituitary hypofunction, and visual field deficits. Rarely, 
PI may be associated with hydrocephalus due to third 
ventricular obstruction, and cranial nerve palsy due to 
cavernous sinus involvement. 
Evaluations of pituitary incidentaloma
PI diagnosed on CT should be further evaluated by 
contrasted MRI of the pituitary region. The visual 
field should be formally assessed for optic chiasm or 
optic nerve compression -  the former being classically 
associated with bitemporal hemianopia, whilst the latter 
may cause loss of vision in the ipsilateral eye and a 
junctional scotoma in the contralateral eye. 
Symptoms of hypersecretion may be very subtle, 
and biochemical evaluation is warranted even when 
no clinical signs and symptoms are detected. This 
is particularly relevant for the diagnosis of silent 
somatotroph and corticotroph adenomas.  Although 
it is not clear whether such lesions are associated 
with the increased risks for metabolic and oncological 
complications like their symptomatic counterparts, 
there is evidence to suggest that these tumours may 
have a worse prognosis than those which produce overt 
symptoms. Early detection and timely management 
is therefore important. In general, up to 40% of 
macroadenomas are associated with hypopituitarism 
and careful endocrinological evaluation is indicated. 
The reported incidence of  hypopituitar ism in 
microadenomas may range from 0 to 50%, and it is 
controversial whether routine screening is necessary.
A detailed discussion of pituitary evaluation is beyond 
the scope of this article. Briefly, screening tests for 
Cushing’s disease include the overnight dexamethasone 
suppression test, the 24-h urinary free cortisol level and, 
more recently, a midnight salivary cortisol level. The 
latter has greater than 93% specificity and sensitivity. 
A random serum insulin-like growth factor-1 (IGF-
1) level is useful for the screening of acromegaly. 
Hyperprolactinaemia may result  from genuine 
hypersecretion or pituitary stalk dysfunction secondary 
to tumour compression. A prolactinoma commonly 
causes a markedly raised PRL level of greater than 
five times the upper limit of normal. A very large 
prolactinoma may produce enough PRL to saturate the 
antibodies in the assays (the ‘hook effect’), resulting in a 
misleadingly low serum PRL level. 
Other tests include total testosterone level in men, 
oestradiol in women, early morning serum cortisol 
for hypocortisolism, and T4 and TSH for secondary 
hypothyroidism. Lutenising hormones (LH), follicular 
stimulating hormone (FSH) and alpha-subunit may 
also be tested as part of the assessment of the gonadal 
axis. Diabetes insipidus is uncommon before surgery 
in the case of PI. The selective loss of a single pituitary 
hormone (e.g., ADH or ACTH) is even rarer and, when 
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associated with a thickened pituitary stalk, should raise 
the suspicion of hypophysitis. 
 
Management of incidental pituitary adenomas
Tumours which are hypersecreting require treatment. 
For non-functioning PIs, the indications for surgery 
include the initial tumour size, the presence of mass 
effect and tumour progression. Not all PIs grow. For 
microadenomas, the lesion size may increase in around 
10%, decrease in 6 %, and remain static in over 80% of 
patients. Upfront surgery is generally not indicated and 
patients may be followed by repeated MRI, initially at 
6-month, then at year-1, -2 and -5. For macroadenoms, 
close to 24 to 50% of cases will increase in size. The 
tumour volume doubling time has been found to vary 
widely from 0.8 to 27.2 years, however. Most authorities 
advocate surgery for incidental macroadenomas given 
their greater propensity for growth. Macroadenomas 
which are managed conservatively should be followed 
up very closely.
Patients with established visual defects certainly require 
treatment. Surgery may also be considered for lesions 
abutting the optic chasm in young patients even in 
the absence of visual field loss. It is controversial if 
hypopituitarism alone would indicate surgery since 
although hypopituitarism is potentially correctable with 
tumour resection, the latter may also cause iatrogenic 
loss of function. Careful counselling is needed especially 
for female patients of reproductive age who may have 
concerns about future child-bearing. Some authorities 
also recommend surgery for lesions which show 
evidence of recent haemorrhages. 
The treatment of choice for most PI is transsphenoidal 
removal. Recent development has seen the increasing 
use of endonasal endoscopic transsphenoidal surgery 
as a minimally invasive alternative to the conventional 
transseptal microscopic approach. Medical therapy alone 
with dopamine agonists or octreotide is effective for only 
10 to   20% of non-prolactinomas but may be considered 
for patients who are unfit for or reluctant to have surgery. 
There is at present not enough evidence to support 
radiosurgery as a standard first-line treatment for PI.
Rathke’s Cleft Cyst (RCC)
Rathke’s cleft cysts are benign lesions commonly 
thought to be the remnants of the Rathke's pouch. The 
cyst content may vary from clear CSF-like to thick 
mucoid-like materials. Histologically, RCCs are lined 
by single or pseudo-stratified cuboidal or columnar 
epithelium although squamous metaplasia can occur 
that may mimic craniopharyngiomas. The incidence of 
RCC found at autopsy is around 13 to 33%.  
It is important but at times difficult to distinguish 
b e t we e n  R C C ,  c y s t i c  p i t u i t a r y  a d e n o m a  a n d 
craniopharyngioma radiologically. These conditions 
have different  natural histories and require very 
different treatment approaches. On CT, all may appear as 
hypo- or isodense lesions although craniopharyngiomas 
are more likely to show calcifications. On MRI, both 
RCC and craniopharyngiomas may show a wide range of 
intensities on T1- and T2-weighted images, depending 
on the nature of the cyst contents. For example, higher 
protein concentrations may lead to shortened T1 and 
T2 relaxation times, increasing the intensity of T1-
weighted and decreasing the intensity of T2-weighted 
images. Rim enhancement may be seen in a number 
of RCCs and may be attributed to the presence of a 
circumscribed area of pituitary tissue, inflammation, 
haemosiderin, cholesterol crystals, or squamous 
metaplasia in the cyst wall. A small intracystic nodule 
corresponding to proteinaceous deposition that has high 
T1 and low T2 intensities, and which does not enhance, 
is a very characteristic appearance of RCC. A RCC with 
hyperintense signals on both T1- and T2-weighted 
images may also resemble a haemorrhagic pituitary 
adenoma.  Recently, diffusion weighted images (DWI) 
have been found to be useful for the distinction between 
these conditions. 3
The majority of RCC are asymptomatic. The common 
clinical presentations resemble those of pituitary 
adenomas, and may include headache, visual field 
loss, and hypopituitarism. The evaluation of a newly 
diagnosed RCC should follow those listed above for PI 
except for hypersecretion, which is not a feature of RCC.
The propensity of growth is relatively low for RCC. 
The majority would remain static. Asymptomatic 
RCCs should be observed. Even those with mild 
symptoms may be managed conservatively because 
some of these lesions have been known to shrink 
or disappear spontaneously. RCCs with significant 
symptoms or increase in size can be readily treated 
surgically by means of transsphenoidal removal. The 
endocrine outcome following surgery, however, remains 
suboptimal - reversal of pituitary deficits is uncommon, 
and diabetes insipidus may occur not infrequently. 
The reported risks of recurrence may range from 8% 
to close to 40%. Surgical biopsy is also indicated when 
a histological exclusion of other sellar pathologies is 
required. 
Summary
Both PI and RCC should receive thorough imaging, 
visual, and hormonal evaluations preferably by 
endocrinologists and neurosurgeons. Due to the 
benign nature of these conditions, most can be 
managed conservatively. The main indications for 
treatment include the presence of visual field deficits, 
hormonal hypersecretion, and disease progression. 
Transsphenoidal resection is the treatment of choice in 
the majority of cases. 
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Introduction 
As with any diagnostic test that screens for diseases, 
the risks of imaging need to be outweighed by 
the benefits of identifying a treatable disease with 
acceptable sensitivity and specificity.  Plain skull X-ray 
with its inherent ionising radiation is therefore not 
recommended for routine assessments of the central 
nervous system except in the detection of skull lesions. 
CT used to be the modality of choice for non-invasive 
assessment of all brain diseases. However with the 
advent of MR, CT is now mainly employed in the 
setting of emergency or trauma in which CT serves as 
the quickest imaging modality for the detection of acute 
intracranial bleeding (traumatic or non-traumatic) and 
skull fractures. 
MR studies of the brain is considered the better imaging 
technique than CT for two reasons.  Firstly, MR has 
a much higher contrast resolution when compared 
with CT for exquisite depiction of normal anatomical 
structures and pathologies of the brain.  Unlike CT 
angiography, intravenous contrast injection is not 
required for MR angiography.  This is advantageous in 
patients with impaired renal function, contrast allergy 
or no intravenous venous access.  Secondly, MRI does 
not involve radiation exposure.  CT brain scans which 
use x-ray to produce images may expose patients to 
about 2 mSv of radiation which is twenty times that of 
chest x-rays. In simple terms, the radiation exposure 
from one non-contrast CT brain study is equivalent to 
the amount of background radiation one experiences in 
about 8 months, considering that the average person in 
Hong Kong receives an effective dose of about 3.2 mSv 
per year from naturally occurring radioactive materials 
and cosmic radiation.  MR imaging has thus replaced 
CT in the imaging of the brain except in patients with 
contraindications to MR, for instance, patients with 
pacemakers or metallic devices.
While MRI study of the brain is increasingly utilised 
in clinical practice and health screening owing to its 
increased availability and recognition among clinicians, 
incidental findings showing abnormalities of potential 
clinical relevance that are unrelated to the purpose of 
the study are unexpectedly discovered on these MR 
brain studies. Reports and studies on the prevalence of 
these incidental abnormalities are growing in number. 
However, the clinical course of some of these incidental 
findings is still uncertain, and their management is not 
standardised.  It is the purpose of this review article to 
categorise the major groups of incidental findings and 
to discuss their clinical relevance.
Prevalence of Incidental MR Brain 
Findings 
No large scale study of incidental MR brain findings 
is available in Hong Kong but the significance of this 
issue is well reflected in studies conducted abroad. 
In a recent systemic review with meta-analysis on 
incidental findings in brain magnetic resonance imaging 
by Morris et al1, it was found that neoplastic incidental 
brain findings had a prevalence of 0.7% (135 of 19559 
people out of 16 studies) with increased prevalence 
with age.  The non-neoplastic incidental findings were 
even more prevalent at 2.0% (375 of 15559 in 15 studies). 
The overall prevalence of incidental brain findings on 
MRI was 2.7 %, equivalent to one for every 37 subjects 
scanned.  
Another remarkable observation is that the prevalence 
was further increased from 1.7% to 4.3% when the 
sensitivity was enhanced by more state-of-the-art 
MR scanners and higher resolution MRI sequences, 
including MR angiography. Nowadays, advanced 
sequences such as three-dimensional T1 spoiled or 
fluid attenuated inversion recovery (FLAIR) or MR 
angiography are commonly included in routine clinical 
scans, leading to discoveries of more incidental findings.
This overall prevalence of 2.7% pointed out by the 
Morris group was in fact  ‘conservative’ as their study 
had already excluded the most common incidental 
findings, namely the white matter hyperintensities 
(WMHs), silent brain infarcts and brain microbleeds 
(BMB). In a study of MRI brain scans on patients of the 
general population2, it was found that the prevalence of 
asymptomatic infarcts was 7.2% (145 of 2000).  
Incidental findings on brain MRI studies can be broadly 
divided into three groups; vascular, neoplastic and non-
neoplastic cystic lesions. This article mainly focuses on 
brain white matter hyperintensities and microbleeds. 
Detailed discussion on other vascular lesions (vascular 
malformations and aneurysms), incidental neoplasms or 
non-neoplastic cysts will be covered by other authors.
White Matter Hyperintensites (WMH) 
& 'Silent' Infarcts 
The most common incidental vascular lesion is white 
matter hyperintensities (WMHs).  These lesions are 
sometimes referred to as leukoaraiosis or age-related 
white matter change (ARWMC).  MRI is highly sensitive 
for the detection of white matter pathologies with 
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Consultant Radiologist, Scanning Department, St. Teresa's Hospital
Medical BulletinVOL.16  NO.2  FEBRUARY  2011
    26
conventional PD or T2 weighted spin echo or fast-spin 
echo sequences but are even more conspicuous on fluid-
attenuated inversion recovery (FLAIR) images. FLAIR 
sequences have the advantage of making cerebrospinal 
fluid (CSF) looks dark while the white matter lesion still 
appears bright. This improves the lesion conspicuity, 
especially in areas close to the CSF spaces such as 
periventricular areas (Figure 1c).
Pathologically,  WMH or ARWMC is an area of 
myelin pallor, tissue rarefaction associated with loss 
of myelin and axons, and mild gliosis.  These lesions 
are most commonly located in the deep white matter 
and often associated with disease of small vessels 
(intraparenchymal cerebral arteries and arterioles), 
which probably induce the WMH lesions through 
chronic or transient but repeated hypoperfusion of 
the white matter. The hypoperfusion results in an 
incomplete form of infarction with disruption of the 
blood-brain barrier, leading to chronic leakage of plasma 
into the white matter and activation of astrocytes.3 
Activated and swollen astrocytes, typically seen in areas 
of WMHs may contribute to the alterations commonly 
detected by MRI.
As the name ARWMC implies ,  the WMHs are 
dependent on the age of patients (Figure 1a and 1b).  In 
the general population, their prevalence shows obvious 
positive correlation with age, ranging from only 4% in 
the age group of 45-59 to 6.8% in age group of 60-74. An 
even higher prevalence of 18.3% was found in the age 
group of 75-974,5.
Figure 1 – Axial T2 weighted images of the same octogenarian 
taken 5 years apart showed obvious progression of the 
white matter hyperintensities (WMHs) in both the deep and 
periventricular white matter.  The confluent periventricular 
WMHs are also more obvious in the parietal lobes (open 
arrow).  These WMHs are well depicted on the coronal FLAIR 
images (figure 1c).  Please note that the age-related prominent 
perivascular spaces (arrows on figure 1b) are confirmed to be 
CSF-filled linear structures on the FLAIR study (arrow on 
figure 1c) with no hyperintense signals.
WMHs are indeed more common and extensive in 
patients with symptomatic cerebrovascular diseases or 
cardiovascular risk factors which include hypertension, 
hypercholesterolaemia, hyperlipidaemia and diabetes 
mellitus among other less common causes. Numerous 
researches have been done on this subject with various 
systems to scale the WMH load either using visual 
assessment (Figure 2) or quantitative analysis. Mild 
lesions are usually punctate lesions less than 5 mm in 
diameter.  The more severe lesions are comprised of 
patchy confluent lesions in the periventricular and deep 
white matter. 
A meta-analysis study by Debette et al6 included 22 
studies which evaluated the association of white matter 
hyperintensities with risks of stroke, cognitive decline, 
dementia or death.  It was concluded WMHs were 
associated with an increased risk of stroke, dementia 
and death. An association with a faster decline in 
global cognitive performance, executive function, and 
processing speed was also suggested.  WMHs therefore 
predict an increased risk of cerebrovascular events. The 
discovery of significant WM load on MR scan should 
prompt detailed screening for risk factors of stroke and 
dementia, especially in relatively young patients. 
Figure 2 – Axial FLAIR images demonstrate different grades of 
white matter hyperintensities (WMHs) in the brain.  Figure 2a in 
a 55-year-old lady shows mild degree of WMHs with only a few 
punctate hyperintense lesions in the subcortical and deep white 
matters (bold arrow). The normal age-related periventricular 
hyperintense smooth thin rims as well as triangular-shaped 
“caps” around the frontal horns (short arrow) are also depicted. 
Figures 2b and 2c in two different elderly gentlemen in their 
seventies show moderate and severe degrees of WMH with 
patchy confluent WMHs in the deep and periventricular white 
matters, most obvious in the parietal lobes.
Brain Microbleed (BMB)
Brain microbleeds (BMBs) are typically seen as tiny 
homogeneous foci of low signal intensity with a 
‘blooming’ appearance on magnetic resonance imaging 
gradient echo (GRE) T2* sequences.  The recently 
introduced susceptibility-weighted imaging (SW) 
can even detect these microhaemorrhages better than 
a gradient-recalled echo sequence due to its high 
sensitivity to blood degradation products7 as in Figure 3.
Pathologically, BMBs are found in areas fed by deep 
perforating arteries showing lipohyalinosis and 
occasional amyloid deposits8 or ruptured arteriosclerotic 
microvessels9. BMB can therefore be considered a 
biomarker of bleeding-prone small-vessel diseases, in 
particular hypertensive small-vessel arteriopathy and 
cerebral amyloid angiopathy (CAA).  
Cordonnier et al10 systematically reviewed and critically 
appraised 54 studies of 53 case series involving 
9073 participants, 4432 of whom were people with 
cerebrovascular diseases. The prevalence of BMBs was 
5% in healthy adults, 34% in people with ischaemic 
stroke,  and 60% in people with non-traumatic 
intracerebral haemorrhage (ICH). BMBs were more 
prevalent among recurrent strokes than first-ever 
strokes; recurrent intracerebral haemorrhage (ICH) than 
first-ever ICH.  
BMBs are usually related to hypertensive illness, 
especially in the setting of uncontrolled or untreated 
patients.  In elderly patients, old microbleeds can also 
be related to amyloid angiopathy which occurs mainly 
in older patients. In CAA, accumulation of amyloid 
β-protein renders vessel walls less elastic and more 
fragile, resulting in microhaemorrhages.
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Although a definite relationship of BMB and use of 
antiplatelet treatment cannot be established, it may be 
prudent in taking extra caution in administrating this 
kind of drug to patients who have a significant degree of 
BMB on MR brain. There was one study 11 considering 
BMB a biomarker for bleeding-prone small-vessel 
diseases and might be associated with antiplatelet-
related ICH.   The risks of ICH could outweigh the 
benefits of antiplatelet therapy in patients with 
significant lobar microbleeds.  In another local study of 
BMB as a risk factor for aspirin-associated ICH12, it was 
found that BMBs are more frequent and more extensive 
in the intracerebral haemorrhage group than in the 
control group.
Figure 3 – Axial GRE T2* weighted and susceptibility-
weighted images of a 65 years old patient with poorly 
controlled hypertension.  Multiple old microbleeds are 
demonstrated at the thalami and basal ganglia (arrow).  The 
subcortical microbleeds are only vaguely seen on GRE T2* 
weighted sequence (figure 3a) but appear more conspicuous and 
numerous on the SWI.
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Faculty of Medicine
The Chinese University of Hong Kong
Postgraduate Diploma in End-of-Life Care
September 2011 admission
The First Postgraduate Diploma course on end- of- life care in Hong Kong
This one year part-time programme provides knowledge base on the theories, 
principles and approach needed for those involved in end of life care in different 
specialties and health care settings. The course will provide a broad coverage of wide 
ranging aspects, from global issues and concerns of end of life, to the care for 
physical, psychological, social and spiritual needs of dying patients and the 
challenging clinical and ethical dilemma; from basic principles of communication, 
counseling with terminally ill patients, to bereavement support and care for carers. The 
programme consists of lectures, case studies and written examinations.
Following the successful commencement of this diploma in year 2007, further topics 
on paediatrics perspectives, surgical perspectives, non-cancer perspectives in organ 
failures & frailty syndromes, funeral and last office arrangements etc had been added 
in the curriculum.
Admission requirements: Bachelors degree in health or social sciences from a 
recognised university, with honours not lower than second class, or course equivalent 
to honours degree. Fulfilled “English Language Proficiency Requirement” as stipulated 
by the Graduate School before being considered for admission.
Course duration and fees: One year part time. HK$42,500 for the academic year 
2011-2012.
Advisor: Prof Jean Woo                        
Course Director: Prof Timothy Kwok        Deputy Course Director: Dr Raymond Lo
Information Seminar:  
Date/Time:  07 March 2011 (Monday) 7:00 p.m. – 8:00 p.m.
Venue: Seminar Room 1, 2/F., Clinical Sciences Building
 Prince of Wales Hospital, Shatin, N.T. 
*****Please contact us to reserve a place*****
Enquiries:
Contact: Ms Dora Pang         Tel: 9168 7005              Fax: 2604 8091            
Email:  dorapang@cuhk.edu.hk 
Website: http://www.mect.cuhk.edu.hk/postgraduate/PgD-EoLC/
Forms and relevant materials are obtainable from us at Room 124021, 10/F., Clinical 
Sciences Building, Prince of Wales Hospital, Shatin, N.T. or you can make an online 
application through our Graduate School at http://www.cuhk.edu.hk/gss.
Application Deadline:31 May 2011
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News from Member Societies
1. Hong Kong College of Paediatricians
Updated office-bearers for the year 2010-2011 are as follows: President: Prof. Pak-cheung NG; Honorary 
Secretary: Dr. Winnie Wing-yee TSE; Honorary Treasurer: Dr. Chi-sik CHAN
2. The College of Dental Surgeons of Hong Kong
Updated office-bearers for the year 2010-2011 are as follows: President: Dr. Roch K.H. LEE; Honorary Secretary: 
Dr. Edmond H.N. POW; Honorary Treasurer: Dr. Alfred C.C. TSANG
3. The Hong Kong Society for Colposcopy and Cervical Pathology
Updated office-bearers for the year 2010-2011 are as follows: President: Dr. Siu-keung LAM; Honorary Secretary: 
Dr. So-fan YIM; Honorary Treasurer: Dr. Alice CHAN
4. The Hong Kong Society of Occupational and Environmental Medicine
Updated office-bearers for the year 2010-2011 are as follows: President: Dr. Mandy Mang-yee HO; Honorary 
Secretary: Dr. Joan Pui-chu FOK; Honorary Treasurer: Dr. Wai-man WOO
The FMSHK would like to send its congratulations to the new office-bearers and look forward to working 
together with the societies. 
Society News
Venue or Meeting
Facilities
Member Society
(Hourly Rate HK$)
Peak
Hour
Non-Peak
Hour
All day 
Sats, Suns & 
Public Holidays 
Rental Fees of Meeting Room and Facilities 
at The Federation of Medical Societies of Hong Kong
Non-Member Society
(Hourly Rate HK$)
Multifunction Room I 
(Max 15 persons)
Council Chamber 
(Max 20 persons)
Lecture Hall 
(Max 100 persons)
150.00
240.00
300.00
105.00
168.00
210.00
225.00
360.00
450.00
250.00
400.00
500.00
175.00
280.00
350.00
375.00
600.00
750.00
Peak
Hour
Non-Peak
Hour
All day 
Sats, Suns & 
Public Holidays 
(Effective from October 2009)
Non-Peak Hour: 9:30am - 5:30pm
Peak Hour: 5:30pm - 10:30pm
LCD Projector 
Microphone System 
500.00 per session
50.00 per hour, minimum 2 hours
Upcoming Certiﬁcate Courses of the Federation of Medical Societies of Hong Kong
01/04/2011 - 13/05/2011
06/04/2011 - 11/05/2011
Medical and Health Professionals
General Practitioners, Health 
Care Providers and Public Who 
Are Interested in Common 
Kidney Problems in Children
9 CNE Points; CME/CPD 
Accreditation in application
9 CNE Points; CME/CPD 
Accreditation in application
Certiﬁcate Course on 
Management of Common 
Psychiatric Disorders 2011 
Certiﬁcate Course on Paediatric 
Nephrology 2011
C173
C176
Date Course No Target ParticipantsCourse Name CME/CNE 
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VOL.16  NO.2  FEBRUARY  2011 Calendar of Events
THU
Ms. Candice TONG            
Tel: 2527 8285                         
CME Accreditation in Application24 Managing BPH in 2011Organiser: HKMA Yau Tsim Mong Community Network, Speaker: Dr Szeto Shek, Petrus
SAT
SUN
Ms. Candice TONG 
Tel: 2527 8285                                           
CME Accreditation in Application26
PPI Lecture Series_Acute Abdominal Pain
Organiser: HKMA Hong Kong East Community Network, Speaker: Dr. Tsang Kin Lun
Tel: 2595 6362  Fax: 2505 7101             
Email: info@icds-hk.org
International Colorectal Disease Symposium 2011
Organiser: Minimal Access Surgery Training Centre & Hong Kong Society for 
Coloproctology, Venue: HKEC Training Centre for Healthcare Management and 
Clinical Technology, Location: Pamela Youda Nethersole Eastern Hospital 
Miss Y.C. YEUNG 
Tel: 3119 1858   Fax: 2301 2414                         
27 CNE Points (Total 9 sessions) 
中醫藥理論精華與中西醫給合專題療護課程 - Session 1:中醫理精華簡介與運用
Organiser: Hong Kong Association for Integration of Chinese-Western Medicine, 
Chairman: Dr. Yu Chau Leung, Edwin, , Speaker: 陳平順博士, Venue: SGN, G/F., Rm 08 
Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong 
TUE
Ms. Christine WONG          
Tel: 2527 8285         1 HKMA Council MeetingOrganiser: The Hong Kong Medical Association, Chairman: Dr. K Choi, Venue: HKMA Head Oﬃce (5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong)
Date  / Time Function Enquiry / Remarks
8:00pm
SAT
Ms. Clara Tsang                 
Tel: 2354 2440                          
2 CME Points12
Refresher Course for Health Care Providers 2010/2011
Organiser: The Hong Kong Medical Association, Speaker: Dr. LEE Ching Yin, Venue: 
OLMH
2:30pm
THU
Ms. Sonia CHEUNG                         
Tel: 2527 8898    Fax: 2865 034510 FMSHK Officers' MeetingOrganiser: The Federation of Medical Societies of Hong Kong, Venue: Gallop, 2/F., Hong Kong Jockey Club House, Shan Kwong Road, Happy Valley, Hong Kong 
2:30pm
SUN
Miss Viviane LAM          
Tel: 2527 8452                        
3 CME Points13 HKMA Certificate Course on Family Medicine 2011Organiser: The Hong Kong Medical Association, Speaker: Dr. TAM Kui Fu, Stanley; Dr. WONG Wai Hong, Venue: QEH
TUE
WED
Ms. Candice TONG       
Tel: 2527 828515
TUE22
Allergic Airway Diseases and Asthma
Organiser: HKMA Kowloon West Community Network, Speaker: Dr. TAM Yat Cheung, 
Alfred, Venue: Panda Hotel
Dr. Gilberto LEUNG                   
Tel: 2255 3368   Fax: 2818 4350                         
1.5 CME Points16
Hong Kong Neurosurgical Society Monthly Academic Meeting - Congenital 
craniocervical abnormalities & Open forum on the future development of neurosurgery 
as a specialty in HK
Organiser: Hong Kong Neurosurgical Society,Chairman:Dr. Sui-to WONG, Speaker:Dr. 
Chun-pong TSANG, Venue: Multifunction Room, Ground Floor, Block D, Queen 
Elizabeth Hospital
2:00pm
7:30am
THU
Miss Viviane LAM        
Tel: 2527 8452                      
1 CME Point17 HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year 2011 – Pain ManagementOrganiser: The Hong Kong Medical Association, Speaker: Dr. LI Ching Fan, Carina, 
Venue: The HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese Club 
Building, 21-22 Connaught Road Central, Hong Kong
2:00pm
Tel: (852) 2585 3312                         
Email:conferencesasia@economist.com
Tel: 2585 3312                         
Email:conferencesasia@economist.com
Economist Conferences: Healthcare in Asia 2011
Organisation: The Economist Group, Venue: Harbour Grand Kowloon Hong Kong, 
Website:www.economistconferences.com/health2011
Miss Carman WONG    
Tel: 2527 8285
Public Education Day at NTW district
Organiser:The Hong Kong Medical Association, Venue: Tuen Mun Town Plaza
3:00pm
FRI
Miss Alice TANG   
Tel: 2527 828525
SUN
Miss Queenie LAM         
Tel: 2527 8285                         
4 CME Points20
1:00pm
7:00pm - 10:00pm
7:00pm - 8:30pm
1:00pm
Miss Carman WONG    
Tel: 2527 8285                        
1 CME Point
2:00pm
18
HKMA Shatin Doctors Network – Update on outpatient management of asthma
Organiser: HKMA Shatin Doctors Network,Speaker: Dr. LI Sing Tao, Thomas, Venue: 
Shatin
Certificate Course on Management of Drug Abuse Patients for Family Doctors
Organiser: The Hong Kong Medical Association, Speaker: Dr. CHAN Lam Fung, 
Lambert; Ms. CHUNG Yin Ting, Brenda, Venue: Tuen Mun
Ms. Sonia CHEUNG                         
Tel: 2527 8898   Fax: 2865 0345
FMSHK Executive Committee & Council Meeting
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 
4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong 
HKMA Photographic Society - 1st Seasonal Photo Sharing & Competition 2011 - 
Submission Deadline
Organiser: HKMA Photographic Society, Chairman: Dr. Amy PANG
Miss Queenie LAM
Tel: 2527 8285                        
4 CME Points27 Certificate Course on Management of Drug Abuse Patients for Family Doctors Organiser: The Hong Kong Medical Association, Speaker: Dr. CHEUNG Kin Leung, Ben; Dr. CHENG Chi Man; Ms. CHENG Oi Kwan, Silvia, Venue: Tuen Mun
Tel: 2595 6362   Fax: 2505 7101
Email: info@icds-hk.org
International Colorectal Disease Symposium 2011
Organiser: Minimal Access Surgery Training Centre & Hong Kong Society for 
Coloproctology, Venue: HKEC Training Centre for Healthcare Management and 
Clinical Technology, Location: Pamela Youda Nethersole Eastern Hospital 
Tel: 2595 6362   Fax: 2505 7101              
Email: info@icds-hk.org
International Colorectal Disease Symposium 2011
Organiser: Minimal Access Surgery Training Centre & Hong Kong Society for 
Coloproctology, Venue: HKEC Training Centre for Healthcare Management and 
Clinical Technology, Location: Pamela Youda Nethersole Eastern Hospital 
The Secretariat of The Federation 
of Medical Societies of Hong Kong 
Tel:2527 8898   Fax:2865 0345
Email:info@fmshk.org               
9 CNE Points (Total 6 sessions)
Certificate Course on Dental Nursing in Oral Surgery
Jointly organised by The Federation of Medical Societies of Hong Kong and The Hong 
Kong Association of Oral and Maxillofacial Surgeons Limited, Topic: Minor Oral 
Surgery in Dental Oﬃce, Speaker: Dr. Julianna Cho-hwei LIEW, Venue: Lecture Hall, 
4/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
The Secretariat of The Federation 
of Medical Societies of Hong Kong 
Tel: 2527 8898   Fax: 2865 0345 
Email:info@fmshk.org               
9 CNE Points (Total 6 sessions)
Certificate Course on Dental Nursing in Oral Surgery
Jointly organised by The Federation of Medical Societies of Hong Kong and The Hong 
Kong Association of Oral and Maxillofacial Surgeons Limited, Topic: Common Oral 
Diseases and Oral & Maxillofacial Surgery, Speaker: Dr. Ken Wai-kuen CHIU, Venue: 
Lecture Hall, 4/F., Duke of Windsor Social Service Building, 15 Hennessy Road, 
Wanchai, Hong Kong
7:00pm - 8:30pm
7:00pm - 10:00pm
Economist Conferences: Healthcare in Asia 2011
Organisation: The Economist Group, Venue: Harbour Grand Kowloon Hong Kong, 
Website:www.economistconferences.com/health2011
FRI
Course / Meeting
中醫藥理論精華與中西醫給合專題療護課程 
Organiser: Hong Kong Association for Integration of Chinese-Western Medicine, Chairman: Dr. Yu Chau Leung, Edwin, 
Venue: SGN, G/F., Rm 08 Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, Tel: 3119 1858, 
Fax: 2301 2414, 27 CNE Points (Total 9 Sessions) 
24/02- 
28/04/2011

